Boehringer Ingelheim today announced that the FIBRONEER-IPF trial met its primary endpoint, which was the absolute change ...
INGELHEIM, Germany I 16, 2024 I Boehringer Ingelheim announced today that the FIBRONEERâ„¢-IPF trial met its primary endpoint, which was the ...
Eli Lilly is the clear frontrunner to be the largest pharmaceutical stock in 2034. See what its prospects are for the next ...
Boehringer Ingelheim acquires Saiba Animal Health, adding innovative technology platform to its pet therapeutics R&D ...
Boehringer Ingelheim announces plans to advance potential new treatment for Geographic Atrophy, following positive Phase I results GlobeNewswire September 05, 2024 Ingelheim, Germany and Basel, ...
Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded ...
There have been tens of thousands of lawsuits since 2020 and there are no doubt many more in the pipeline but few have gone to trial ... unable to decide whether German pharmaceutical Boehringer ...
11d
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...
Fatty liver disease linked to diabetes and obesity can easily progress to liver cirrhosis, but new research suggests that GLP ...
Oral Solid Dosage Pharmaceutical Formulation Market is projected to achieve US$ 8,95,636.0 million by 2034 at a CAGR of 3.7%.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback